NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Proceeds will go toward expanding the San Diego-based firm's R&D operations and capabilities to commercialize its platform for the molecular characterization of circulating tumor cells in blood. The technology is licensed from Peter Kuhn's laboratory at The Scripps Research Institute.
Epic currently has collaborations with seven pharmaceutical firms to develop companion diagnostics for oncology drug candidates, it said, including a number of partnerships in Phase I and II clinical trials.
The Series B round includes new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as unnamed individual investors. Kim Kamdar, a partner in Domain, is joining Epic's board in conjunction with the financing, Epic said.